Lv2
127 积分 2025-10-28 加入
Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
2天前
已完结
A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry
3天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
4天前
已完结
Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)
4天前
求助中
An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes
10天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
15天前
已完结
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
2个月前
已完结
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
3个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
3个月前
已完结
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
3个月前
已完结
皖公网安备34019202002308
